Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- Teijin Pharma: Bonalon IV Infusion Approved as Japan’s 1st Once-a-Month IV Drug for Osteoporosis
January 20, 2012
- Takeda to Cut 2,800 Jobs in US, Europe by Integrating Operation Sites
January 19, 2012
- Takeda President Hasegawa Envisions Japanese National as Successor
January 19, 2012
- Takeda’s Next Core Product, Novel ARB Azilva Approved
January 19, 2012
- Senju Obtains Approval for Glaucoma Treatment Aiphagan
January 19, 2012
- Daiichi Sankyo to Copromote 1st Antibody Drug with AstraZeneca
January 19, 2012
- Nexium Dominates Top 2 Rankings in HP Market 2 Months in a Row: RepTrack Dec. Survey
January 18, 2012
- AZ Appeals Effectiveness of Faslodex as Secondary Treatment
January 18, 2012
- BTMU Forecast 1% Growth in 2012 Domestic Ethical Drug Market
January 18, 2012
- Hisamitsu Starts Capital, Business Alliance with Yutoku Following Acquisition of 15% of Its Shares
January 18, 2012
- Eisai: Insomnia Treatment Lunesta Approved
January 18, 2012
- Astellas: Regnite Approved for RLS
January 18, 2012
- MSD: Cancidas Approved for Treatment of Deep Mycoses
January 18, 2012
- Otsuka: Abilify Obtains Add’l Indication for Manic Symptoms in Bipolar Disorder, OD Tablets as Well
January 18, 2012
- MSD: Rotavirus Vaccine RotaTeq Oral Solution Approved
January 18, 2012
- Nobelpharma and Eisai Launch Anticonvulsant Agent Fostoin on Jan. 17
January 17, 2012
- MTPC Licenses Hib Vaccine from Nuron Biotech
January 17, 2012
- 38% of Doctors Will Attend Company-Sponsored Events Only if Transportation, Lodging Costs Are Paid: Survey
January 17, 2012
- 100th Acquisition/License Support Agreement Reached through LSIP Fund
January 17, 2012
- MTPC Issues Apology for Its Researcher’s Arrest on Suspicion of Bodily Harm
January 16, 2012
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…